RALEIGH N.C.--(BUSINESS WIRE)--June 21, 2006--Sicel Technologies, Inc., announced today that the Company has received FDA clearance to market DVS® (Dose Verification System), its wireless, implantable radiation sensor and reader for a second indication. The product's clearance for use in prostate cancer comes two months after the FDA cleared the product for use in breast cancer and follows the completion of a multi-center clinical study evaluating safety and efficacy. Using the hand-held reader, physicians were able to determine the actual dose of radiation being delivered to the tumor after each treatment.
